The Trump administration’s April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, while leaving non-medical marijuana in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling from Schedule I to III began June 29, 2026, before an administrative law judge and concluded no later than July 15; only opponents of rescheduling were selected to participate. The DEA has defended the proposal in post-hearing briefs, citing accepted medical use and safety data from state programs. A federal appeals court in September 2026 rejected efforts to stay the process. Resolution of the broader rulemaking now depends on the ALJ recommendation, any final agency rule, and ongoing litigation, with no firm timeline for completion beyond the hearing record.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert$810,189 Vol.
30. Sep. 2026
30. September
2%
31. Dezember
16%
$810,189 Vol.
30. September
$679 Vol.
2%
31. Dezember
$199,939 Vol.
16%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration’s April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, while leaving non-medical marijuana in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling from Schedule I to III began June 29, 2026, before an administrative law judge and concluded no later than July 15; only opponents of rescheduling were selected to participate. The DEA has defended the proposal in post-hearing briefs, citing accepted medical use and safety data from state programs. A federal appeals court in September 2026 rejected efforts to stay the process. Resolution of the broader rulemaking now depends on the ALJ recommendation, any final agency rule, and ongoing litigation, with no firm timeline for completion beyond the hearing record.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Markt eröffnet: Jul 31, 2026, 5:46 PM ET
Volumen
$810,189Enddatum
1. Jan. 2027Markt eröffnet
Jul 31, 2026, 5:46 PM ETAbwickler
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration’s April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, while leaving non-medical marijuana in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling from Schedule I to III began June 29, 2026, before an administrative law judge and concluded no later than July 15; only opponents of rescheduling were selected to participate. The DEA has defended the proposal in post-hearing briefs, citing accepted medical use and safety data from state programs. A federal appeals court in September 2026 rejected efforts to stay the process. Resolution of the broader rulemaking now depends on the ALJ recommendation, any final agency rule, and ongoing litigation, with no firm timeline for completion beyond the hearing record.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$810,189Enddatum
1. Jan. 2027Markt eröffnet
Jul 31, 2026, 5:46 PM ETAbwickler
0x65070BE91...The Trump administration’s April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, while leaving non-medical marijuana in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling from Schedule I to III began June 29, 2026, before an administrative law judge and concluded no later than July 15; only opponents of rescheduling were selected to participate. The DEA has defended the proposal in post-hearing briefs, citing accepted medical use and safety data from state programs. A federal appeals court in September 2026 rejected efforts to stay the process. Resolution of the broader rulemaking now depends on the ALJ recommendation, any final agency rule, and ongoing litigation, with no firm timeline for completion beyond the hearing record.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen